BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28211277)

  • 1. Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
    Pettit GR; Melody N; Chapuis JC
    J Nat Prod; 2017 Mar; 80(3):692-698. PubMed ID: 28211277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
    Pettit GR; Melody N; Chapuis JC
    J Nat Prod; 2017 Sep; 80(9):2447-2452. PubMed ID: 28895394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.
    Pettit GR; Hogan F; Toms S
    J Nat Prod; 2011 May; 74(5):962-8. PubMed ID: 21534541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic Agents. 605. Isoquinstatins.
    Pettit GR; Melody N; Chapuis JC
    J Nat Prod; 2018 Mar; 81(3):451-457. PubMed ID: 28926240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
    Singh SB
    J Nat Prod; 2022 Mar; 85(3):666-687. PubMed ID: 35072477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates.
    Maderna A; Leverett CA
    Mol Pharm; 2015 Jun; 12(6):1798-812. PubMed ID: 25697404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic agents 365. Dolastatin 10 SAR probes.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
    Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis and biological activity of dolastatin 16.
    Casalme LO; Yamauchi A; Sato A; Petitbois JG; Nogata Y; Yoshimura E; Okino T; Umezawa T; Matsuda F
    Org Biomol Chem; 2017 Feb; 15(5):1140-1150. PubMed ID: 28074955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineoplastic Agents. 607. Emetine Auristatins.
    Pettit GR; Melody N; Chapuis JC
    J Nat Prod; 2020 May; 83(5):1571-1576. PubMed ID: 32323990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
    Pettit GR; Hogan F; Herald DL
    J Org Chem; 2004 Jun; 69(12):4019-22. PubMed ID: 15176826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antineoplastic agents. 599. Total synthesis of dolastatin 16.
    Pettit GR; Smith TH; Arce PM; Flahive EJ; Anderson CR; Chapuis JC; Xu JP; Groy TL; Belcher PE; Macdonald CB
    J Nat Prod; 2015 Mar; 78(3):476-85. PubMed ID: 25689568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.
    Dugal-Tessier J; Barnscher SD; Kanai A; Mendelsohn BA
    J Nat Prod; 2017 Sep; 80(9):2484-2491. PubMed ID: 28885014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
    Maderna A; Doroski M; Subramanyam C; Porte A; Leverett CA; Vetelino BC; Chen Z; Risley H; Parris K; Pandit J; Varghese AH; Shanker S; Song C; Sukuru SC; Farley KA; Wagenaar MM; Shapiro MJ; Musto S; Lam MH; Loganzo F; O'Donnell CJ
    J Med Chem; 2014 Dec; 57(24):10527-43. PubMed ID: 25431858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of Dolastatin 15 mimetic peptoids.
    Schmitt J; Bernd M; Kutscher B; Kessler H
    Bioorg Med Chem Lett; 1998 Feb; 8(4):385-8. PubMed ID: 9871690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
    Yokosaka S; Izawa A; Sakai C; Sakurada E; Morita Y; Nishio Y
    Bioorg Med Chem; 2018 May; 26(8):1643-1652. PubMed ID: 29454703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.
    Gao G; Wang Y; Hua H; Li D; Tang C
    Mar Drugs; 2021 Jun; 19(7):. PubMed ID: 34202685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic agents. 600. From the South Pacific Ocean to the silstatins.
    Pettit GR; Arce PM; Chapuis JC; Macdonald CB
    J Nat Prod; 2015 Mar; 78(3):510-23. PubMed ID: 25688575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.
    Yang K; Chen B; Gianolio DA; Stefano JE; Busch M; Manning C; Alving K; Gregory RC; Brondyk WH; Miller RJ; Dhal PK
    Org Biomol Chem; 2019 Sep; 17(35):8115-8124. PubMed ID: 31460552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.